5-Year Follow-Up After Primary Percutaneous Coronary Intervention With a Paclitaxel-Eluting Stent Versus a Bare-Metal Stent in Acute ST-Segment Elevation Myocardial Infarction A Follow-Up Study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction With ST-Segment Elevation) Trial by Vink, Maarten A. et al.
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ackground In primary percutaneous coronary intervention for acute ST-segment elevation myocar-
ial infarction (STEMI), the use of drug-eluting stents (DES) is still controversial. Several randomized
ontrolled trials of DES, compared with bare-metal stents (BMS), with short-term follow-up showed a
eduction in target lesion revascularization (TLR), but no differences in rates of cardiac death or re-
urrent myocardial infarction. Moreover, the occurrence of (very) late stent thrombosis (ST) contin-
es to be of major concern, and, therefore, long-term follow-up results are needed.
ethods We randomly assigned 619 patients presenting with STEMI to a paclitaxel-eluting stent
PES) or the similar BMS. The primary end point was the composite of cardiac death, recurrent myo-
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ion, or TLR was comparable at 18.6% versus 21.8% in PES and BMS, respectively (hazard ratio [HR]:
.82, 95% conﬁdence interval [CI]: 0.58 to 1.18, p  0.28). The incidence of deﬁnite or probable ST
as 12 (4.2%) in the PES group and 10 (3.4%) in the BMS group (HR: 1.19, 95% CI: 0.51 to 276, p 
.68).
onclusions In the present analysis of PES compared with BMS in primary percutaneous coronary
ntervention for STEMI, no signiﬁcant difference in major adverse cardiac events was observed. In
ddition, no difference in the incidence of deﬁnite or probable ST was seen, although very late ST
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25n acute ST-segment elevation myocardial infarction
STEMI), primary percutaneous coronary intervention
PPCI) with stenting has proven to be the optimal treat-
ent compared with medical therapy or angioplasty alone
1,2). After their introduction, drug-eluting stents (DES)
roved to reduce neointima hyperplasia compared with
are-metal stents (BMS), when implanted in patients with
table coronary artery disease (3,4). Subsequently, several
See page 39
egistries and randomized controlled trials have tried to
xplore the possible advantage of the use of DES in STEMI
5–8). In most trials published, the implantation of either
aclitaxel-eluting stents (PES) or sirolimus-eluting stents
esulted in lower rates of repeat revascularization, but none
f these trials showed an advantage in mortality or recurrent
yocardial infarction (MI), compared with conventional
MS.
With the ongoing concern of a possible higher frequency
f stent thrombosis (ST) occurring very late (beyond 1 year)
fter implantation of DES (9,10), routine implementation
f DES in PPCI is still not widely accepted (11,12).
vailable data of retrospective studies suggest higher rates
f ST, even several years after implantation of DES in
PCI, compared with stenting for stable angina (13,14). In
he present analysis, we performed clinical follow-up 5 years
fter inclusion in the PASSION (Paclitaxel-Eluting Versus
onventional Stent in Myocardial Infarction with ST-
egment Elevation) trial, in which patients were random-
zed to a PES or a conventional BMS in PPCI. The aim was
o elucidate a possible long-term benefit of DES over BMS
n STEMI in terms of major adverse cardiac events
MACE) and to address the concern of (very) late ST.
ethods
tudy design. Between March 2003 and December 2004,
19 patients were included in the PASSION trial. The
ASSION trial was a prospective, single-blind, randomized
tudy, performed at 2 centers in the Netherlands (Onze
ieve Vrouwe Gasthuis, Amsterdam, and Sint Antonius
iekenhuis, Nieuwegein). The study has been registered as
n International Randomized Controlled Trial.
Both details of study design and the results of clinical
ollow-up have been published previously (5,15).
rocedures. After arrival at the hospital, we first adminis-
ered a loading dose of aspirin (100 to 500 mg) and
lopidogrel (300 mg), followed by aspirin 80 to 100 mg once
aily for life and clopidogrel 75 mg once daily for at least 6
onths. A bolus of 10,000 IU of unfractionated heparin was
dministered before the procedure. The use of glycoprotein
Ib/IIIa receptor inhibitors was at the discretion of the
perator, as were the use of pre-dilation balloons and rhrombus aspiration devices. After coronary angiography
atients were randomized in a 1:1 ratio using permuted
locks of 50, to receive either a PES (Taxus Express2,
oston Scientific, Natick, Massachusetts) or a BMS with
he same platform (Express2 or Liberté, Boston Scientific).
ollow-up. After the initial hospital discharge, patients were
ontacted by phone or mail at pre-defined intervals. All
dverse cardiac events were recorded during each patient’s
ospital stay, as well as during follow-up visits at 30 days, 6
onths, 1 year, 2 years, and 5 years after randomization. In
he case of an event, information was obtained from hospital
ecords or from the treating cardiologist. If the patient could
ot be reached, vital status and date of death (if applicable)
as obtained from local authorities.
nd points. G.J.L. and M.J.S. adjudicated all end points in
blinded fashion. The primary end point was the first
ccurrence of MACE, defined
s the composite of cardiac
eath, recurrent MI, or target-
esion revascularization (TLR),
ither by PCI or coronary artery
ypass grafting. A secondary end
oint was the occurrence of ST,
s determined by the Academic
esearch Consortium (16). Def-
nite ST was defined as angio-
raphic confirmation of vessel
cclusion or proven ST either
y angiography or at autopsy
ithin, or adjacent to, the
tented segment. Probable ST
as defined as unexplained
eath within 30 days, or target-
essel recurrent MI without an-
iographic confirmation. When
nexplained death occurred be-
ond 30 days, it was classified as
ossible ST. Stent thrombosis
as categorized according to timing of the event after stent
mplantation and divided into acute ST (24 h), subacute
T (between 24 h and 30 days), late ST (30 days to 1 year),
nd very late ST (beyond 1 year).
tatistical analysis. Baseline data are presented as propor-
ions or mean (SD) values and were compared using
tudent t test or Wilcoxon rank-sum test for continuous
ariables and Fisher exact test for categorical variables. A
-sided p value 0.05 was considered to indicate statistical
ignificance. We estimated the cumulative incidence rates of
he primary and secondary end points at 5 years with the
aplan-Meier method. Hazard ratios (HRs) with 95%
onfidence intervals (CIs) were calculated with Cox
roportional-hazards models with treatment allocation as
he only variable. The significance of differences in event
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
PPCI  primary
percutaneous coronary
intervention
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
STEMI  ST-elevation
myocardial infarction
TLR  target-lesion
revascularizationates between treatment groups was assessed by the log-rank
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26est. Statistical analysis was done with SPSS (version 16.0
or Windows, SPSS, Inc., Chicago, Illinois).
esults
total of 310 patients were randomized to receive a PES
nd 309 to a BMS. Baseline clinical characteristics were well
atched (Table 1). In addition, angiographic and proce-
ural characteristics were similar between both groups
Table 2). Approximately 50% of patients underwent
hrombus aspiration before stenting, and the use of a
lycoprotein IIb/IIIa receptor inhibitor was comparable in
he PES and BMS groups, with rates of 73.2% and 74.4%,
espectively.
linical follow-up at 5 years. At 5-year follow-up, complete
ata on vital status was available for 98.7% of patients.
omplete datasets on all clinical events were available for
7.6% of patients. The results are stated in Table 3. The
omposite end point of cardiac death, recurrent MI, or TLR
as reached in 56 (18.6%) versus 66 (21.8%) patients in the
ES and the BMS groups, respectively (HR: 0.82, 95% CI:
.58 to 1.18; p  0.28). Figure 1 shows the Kaplan-Meier
urve for the incidence of the primary end point. With 7.7%
n the PES group and 10.5% in the BMS group, a slight
rend toward a lower incidence of TLR was observed in
avor of PES (HR: 0.71, 95% CI: 0.41 to 1.23; p  0.21).
he occurrence of cardiac death or MI was comparable
etween both groups (15.0% vs. 14.6%; HR: 1.02, 95% CI:
.67 to 1.55; p  0.92). Cardiac death rates at 5 years were
elatively low, at 8.9% in the PES group versus 11.5% in the
MS group (HR: 0.76, 95% CI: 0.46 to 1.25, p  0.28).
e performed a landmark analysis of the occurrence of the
rimary end point between 1 and 5 years (Fig. 2). At a rate
f 10.8% in the PES group, and 10.2% in the BMS group
Table 1. Baseline Clinical Characteristics
Variable
PES
(n  310)
BMS
(n  309) p Value
Age, yrs 61 12 61 13 0.91
Male 229 (73.9) 241 (78.0) 0.26
Diabetes mellitus 31 (10.0) 37 (12.0) 0.44
Hypertension 95 (30.6) 98 (31.7) 0.80
Hypercholesterolemia 72 (23.2) 86 (27.8) 0.20
Family history of CAD 125 (40.3) 110 (35.6) 0.25
Smoking 165 (53.2) 154 (49.8) 0.42
Previous PCI 14 (4.5) 13 (4.2) 1.00
Previous stent 5 (1.6) 6 (1.9) 0.77
Previous CABG 2 (0.6) 2 (0.6) 1.00
Previous MI 14 (4.5) 18 (5.8) 0.48
Anterior infarction 158 (51.0) 158 (51.1) 0.97
Values are expressed as mean SD or n (%).
BMS  bare-metal stent(s); CABG  coronary artery bypass grafting; CAD  coronary artery
disease; MImyocardial infarction; PCI percutaneous coronary intervention; PES paclitaxel-Teluting stent(s).HR: 1.07, 95% CI: 0.63 to 1.82; p  0.80), no difference
n the occurrence of late events was seen.
tent thrombosis. The occurrence of definite or probable
T up to 5 years was comparable between both groups, with
2 (4.2%) in the PES group and 10 (3.4%) in the BMS
roup (HR: 1.19, 95% CI: 0.51 to 2.76; p  0.68) (Fig. 3).
efinite ST occurred in 11 (3.9%) and 5 (1.7%) patients in
he PES and BMS groups, respectively (HR: 2.19, 95% CI:
.76 to 6.29; p 0.14). The incidence of (very) late definite
r probable ST was higher in the PES group than the BMS
roup, at 10 (3.5%) versus 3 (1.1%), p  0.06. Similarly,
very) late definite ST occurred in 9 (3.3%) patients in the
ES group versus 2 (0.7%) in the BMS group, p  0.04
Table 4).
iscussion
reviously, we published the 1-year clinical outcomes of the
ASSION trial (5). This report did not show a difference in
Table 2. Baseline Angiographic and Procedural Characteristics
Variable
PES
(n  310)
BMS
(n  309) p Value
Symptom to balloon, min 180 102 178 108 0.86
Sum of ST-segment elevation, mm 11 8 11 9 0.76
Infarct-related artery
Left anterior descending artery 156 (50.3) 154 (49.8) 0.94
Left main stem 2 (0.6) 0 0.50
Right coronary artery 129 (41.6) 118 (38.2) 0.41
Left circumﬂex artery 18 (5.8) 32 (10.4) 0.04
Intermediate branch 3 (1.0) 4 (1.3) 0.72
Saphenous-vein graft 2 (0.6) 1 (0.3) 1.00
Pre-procedural TIMI ﬂow grade
0 193 (62.3) 196 (63.4) 0.80
1 26 (8.4) 25 (8.1) 1.00
2 41 (13.2) 48 (15.5) 0.42
3 50 (16.1) 40 (12.9) 0.30
Reference diameter, mm 3.13 0.43 3.20 0.47 0.04
Visible thrombus 213 (68.7) 204 (66.0) 0.49
Thrombus aspiration 156 (50.3) 155 (50.2) 0.97
Number of stents implanted 1.26 0.55 1.33 0.63 0.14
Stent size, mm 3.21 0.30 3.26 0.38 0.08
Stent length, mm 19 5.6 19 5.5 0.71
Final TIMI ﬂow grade
0 2 (0.6) 3 (1.0) 0.69
1 2 (0.6) 2 (0.6) 1.00
2 17 (5.5) 7 (2.3) 0.06
3 289 (93.2) 297 (96.1) 0.15
GP IIb/IIIa receptor antagonist 227 (73.2) 230 (74.4) 0.78
Procedural success 289 (93.2) 297 (96.1) 0.15
Values are expressed as mean SD or n (%).
GP  glycoprotein; TIMI  Thrombolysis In Myocardial Infarction; other abbreviations as in
Table 1.LR and MACE rate after the use of PES compared with
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27MS. The present analysis shows there is still no significant
ifference observed through 5 years of follow-up. The
azard ratio for TLR at 5 years (HR: 0.71, p  0.21) was
dentical to that observed at 1 year (HR: 0.68, p  0.23).
lthough the hazard ratio for MACE (the composite end
oint of cardiac death, recurrent MI, or TLR) at 5 years still
as in favor of PES, it had somewhat attenuated relative to
hat at 1 year (HR: 0.82, p  0.28 at 5 years vs. HR: 0.69,
 0.12 at 1 year). The attenuation was mainly due to a
lightly higher incidence of ST-related MI in the PES
roup beyond 1 year. Moreover, no difference was seen in
he occurrence of cardiac death or recurrent MI, neither
arly nor late after implantation.
Table 3. Clinical Outcome at 5 Years
Adverse Cardiac Events
PES
(n  310
Cardiac death, recurrent MI, or TLR 56 (18.6)
Cardiac death 27 (8.9)
Recurrent MI 19 (6.8)
Cardiac death or MI 45 (15.0)
TLR 22 (7.7)
Values are expressed as n (%).
Percentages were estimated using the Kaplan-Meier method.
CI confidence interval; HR hazard ratio; TLR target lesion rev
Figure 1. Kaplan-Meier Time-to-Event Curve for the Primary End Point of
the Composite of Cardiac Death, Recurrent MI, or TLR
Graph shows the Kaplan-Meier time-to-event curve for the primary end
point of the composite of cardiac death, recurrent myocardial infarction, or
target lesion revascularization. BMS  bare-metal stent(s); CI  conﬁdence
interval; HR  hazard ratio; MI  myocardial infarction; PES  paclitaxel-
eluting stent(s); TLR  target lesion revascularization.Only short-term results have been published of the other
andomized trials comparing DES with BMS for STEMI.
ur study design was best comparable to that of the
ORIZONS-AMI (Harmonizing Outcomes With Revas-
ularization and Stents in Acute Myocardial Infarction)
rial, in particular with regard to stent usage and the absence
f angiographic follow-up (6). The HORIZONS-AMI
rial, the largest trial so far, reported a 1-year TLR incidence
f 4.5% in PES-treated patients versus 7.5% in BMS-
reated patients (p  0.002). The HORIZONS-AMI
-year results (HR: 0.59 for TLR in favor of PES) were
imilar to those observed in PASSION. The larger number
f patients included in the HORIZONS-AMI trial explains
ts statistical significance, which our study lacked.
Smaller randomized controlled trials of DES in STEMI
ith short-term follow-up showed a similar pattern as
ORIZONS-AMI, with no differences in the incidence of
ardiac death or recurrent MI, although with differences in
he need for TLR favoring DES. In the TYHPOON (Trial
BMS
(n  309) HR 95% CI p Value
66 (21.8) 0.82 0.58–1.18 0.28
35 (11.5) 0.76 0.46–1.25 0.28
2 (4.3) 1.58 0.77–3.26 0.21
44 (14.6) 1.02 0.67–1.55 0.92
30 (10.5) 0.71 0.41–1.23 0.21
ization; other abbreviations as in Table 1.
Figure 2. Kaplan-Meier Time-to-Event Curve of the Primary End Point of
the Composite of Cardiac Death, Recurrent MI, or TLR
Landmark analysis with the incidence up to 1 year and from 1 to 5 years of)follow-up. Abbreviations as in Figure 1.
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28o Assess the Use of the Cypher Stent in Acute Myocardial
nfarction Treated With Angioplasty) trial, which com-
ared sirolimus-eluting stents (SES) with BMS, there was a
ignificant difference in the occurrence of target-vessel
evascularization at 1 year, at 5.6% versus 13.4% (HR: 0.41,
 0.001) in SES and BMS, respectively (7). Likewise, the
-year report of the SESAMI (Sirolimus-Eluting Stent
ersus Bare-Metal Stent in Acute Myocardial Infarction)
rial showed a large absolute difference in TLR in favor of
ES, at 4.3% versus 11.2% (p  0.02) in SES and BMS,
espectively (17). These differences, however, were larger
han those observed in PASSION and HORIZONS-AMI.
he larger differences in repeat revascularization between
he 2 stent groups in both TYPHOON and SESAMI were
ainly due to a much higher incidence in the BMS groups.
ariations in study design may well explain this disparity.
irst, this difference could have been influenced by routine
ngiographic follow-up within the first year after implanta-
ion (18). Our protocol did not include planned angiogra-
hy during follow-up, which might explain the smaller
bsolute difference in TLR between both groups. Further-
ore, the stent platform of the DES used in our study was
he exact same stent platform with which it was compared.
his is an important difference with TYPHOON and
ESAMI, in which a DES was compared with a range of
ypes BMS, possibly resulting in less favorable outcome
fter the use of BMS. Except from the 3-year data of the
ESAMI trial, which showed maintenance of the early
enefit in TLR (19), no long-term clinical outcomes of both
rials have been published.
tent thrombosis. At 1 year, no difference in the occurrence
Figure 3. Kaplan-Meier Time-to-Event Curve for the Occurrence of
Definite or Probable Stent Thrombosis
Graph shows Kaplan-Meier time-to-event curve for the occurrence of deﬁ-
nite or probable stent thrombosis. Abbreviations as in Figure 1.f ST was seen in our study, with a rate of 1.0% in bothroups. These comparable results between DES and BMS
ere in line with those of the HORIZONS-AMI,
YPHOON, and SESAMI trials, although HORIZONS-
MI and TYPHOON showed a higher incidence in both
tent groups, at 2.6% versus 3.0% and 3.4% versus 3.6%,
espectively. This could be explained by a difference in the
efinition of ST and/or, given the low number of events, by
hance. In the meantime, the definitions of ST established
y the Academic Research Consortium provide the oppor-
unity of an unambiguous comparison (16). At 5 years, we
bserved a similar incidence of definite or probable ST, with
2 patients (4.2%) in the PES group and 10 (3.4%) in the
MS group, at a hazard ratio of 1.19 (p  0.68). This
ndicates the safety of both PES and BMS throughout
ollow-up. Worth mentioning, very late ST was almost
xclusively seen after implantation of PES (p  0.06 for
efinite or probable ST, p  0.04 for definite ST). The
resent analysis suggests there might be a small but contin-
ously present risk of ST in the PES group several years
fter cessation of dual-antiplatelet therapy. Our observation
ccords with observations from retrospective studies, show-
ng that ST is associated with DES, with the emphasis on
he risk of very late ST related to implantation in acute
oronary syndromes (13,14,20). Noteworthy, in current
aily practice, PES have been supplanted by newer gener-
tions of DES as subsequently conducted trials showed
uperiority in both efficacy and safety of everolimus-eluting
tents compared with PES (21,22). Nevertheless, long-term
ollow-up of larger trials evaluating the efficacy and safety of
ES in STEMI is necessary to substantiate our findings.
tudy limitations. This study has some limitations. The
vent rates in both groups were lower than anticipated in
ur power calculations. As a result, the estimated relative
isk reduction of 15% in the occurrence of MACE, using
ES compared with BMS, lacked statistical significance. In
ddition, with 619 patients included, the PASSION trial
as not powered to detect differences in the occurrence of
Table 4. Incidence of ST According to Definition of the
Academic Research Consortium, Classified by Timing of Event
ST
PES
(n  310)
BMS
(n  309) HR 95% CI p Value
Deﬁnite or probable ST, n (%) 12 (4.2) 10 (3.4) 1.19 0.51–2.76 0.68
Acute 1 0
Subacute 1 7
Late 2 0
Very late 8 3
Deﬁnite ST, n (%) 11 (3.9) 5 (1.7) 2.19 0.76–6.29 0.14
Acute 1 0
Subacute 1 3
Late 1 0
Very late 8 2
Percentages were estimated using the Kaplan-Meier method.ST stent thrombosis; other abbreviations as in Tables 1 and 3.
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29he safety end point ST. Although we did find a notable
ifference in rates of very late ST between the 2 stent
roups, our findings should be interpreted with caution.
much larger trial would have been needed to demonstrate
tatistical significance. Another limitation of this long-term
ollow-up study is the lack of autopsy data in patients who
ied suddenly, which may well have resulted in underesti-
ation of the real incidence of ST.
onclusions
ur present report is the first 5-year clinical follow-up of a
rospective, randomized trial of DES in STEMI. We
bserved no significant difference in the occurrence of
ACE and TLR in PES compared with BMS. Up to
-years follow-up, no difference in the occurrence of definite
r probable ST was seen, although there might be a higher
ncidence of (very) late ST using PES.
In current clinical practice guidelines, the use of DES in
cute STEMI is mentioned only as a method to reduce
estenosis. Because there is no evidence for a reduction in
he occurrence of death, recurrent MI, or ST, the guidelines
f the European Society of Cardiology or the American
ollege of Cardiology/American Heart Association do not
ake a general recommendation for the use of DES in the
etting of STEMI. Our present analysis is the first to
rovide long-term efficacy and safety data on DES in PPCI.
he possibility of a higher risk of very late ST in PES
upports the ambivalence of the guidelines on this matter,
hich needs to be substantiated in further clinical research.
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